317 related articles for article (PubMed ID: 19364958)
1. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
2. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
Sabatino M; Kim-Schulze S; Panelli MC; Stroncek D; Wang E; Taback B; Kim DW; Deraffele G; Pos Z; Marincola FM; Kaufman HL
J Clin Oncol; 2009 Jun; 27(16):2645-52. PubMed ID: 19364969
[TBL] [Abstract][Full Text] [Related]
3. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
4. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
5. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
6. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
7. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
9. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
10. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
Meyers FJ; O' Donnell RT
Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
[No Abstract] [Full Text] [Related]
11. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
12. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
13. Highlights from the Eigth International Kidney Cancer Symposium.
Hutson T
Clin Adv Hematol Oncol; 2009 Dec; 7(12):796-8. PubMed ID: 20332749
[No Abstract] [Full Text] [Related]
14. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2.
Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
[No Abstract] [Full Text] [Related]
16. Defining an individualized treatment strategy for metastatic renal cancer.
Hu B; Lara PN; Evans CP
Urol Clin North Am; 2012 May; 39(2):233-49, vii. PubMed ID: 22487765
[TBL] [Abstract][Full Text] [Related]
17. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
18. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
19. Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine-2 treatment.
Camerini A; Tartarelli G; Martini L; Donati S; Puccinelli P; Amoroso D
Int J Urol; 2007 Mar; 14(3):259-60. PubMed ID: 17430270
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and prognostic factors.
Fumagalli LA; Brivio F
J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
[No Abstract] [Full Text] [Related]
[Next] [New Search]